Moneycontrol PRO
HomeNewsBusinessStocksCadila up 5%, Credit Suisse bullish on strong US pipeline

Cadila up 5%, Credit Suisse bullish on strong US pipeline

Cadila's price hike of HydroxyChloroquine (antimalarial drug) after IPCA and Ranbaxy exit will add 15 percent to FY16 EPS. The benefit of higher prices and market share is likely to reflect in December 14 quarter results, it adds.

January 05, 2015 / 14:15 IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Moneycontrol Bureau

Shares of Cadila Healthcare jumped 5 percent intraday on Monday after Credit Suisse has maintained an outperform rating on the stock. The brokerage has also increased its target price to Rs 1900 per share indicating a 17 percent potential upside.

Cadila is Credit Suisse’s preferred picks due to strong US pipeline and its next key catalyst is Prevacid approval. 

It believes that Cadila’s price hike of HydroxyChloroquine (antimalarial drug) after IPCA and Ranbaxy exit will add 15 percent to FY16 EPS. The benefit of higher prices and market share is likely to reflect in December 14 quarter results, it adds.

“After the price increase, the Hydroxychloro market increased from USD 25-30 mn to USD 90 mn, and generics now are priced close to 80 percent of innovator price. Six players have FDA approval on the drug but only four have been active. Among these six players, Cadila is the only vertically integrated and is also the first to initiate price increase on 6 August 2014,” Credit Suisse says in report.

It also expects Cadila to increase market share from 30  percent to 50 percent. At 50 percent volume share, it is hopefult that Hydroxychloro will add Rs10 EPS to FY16 or 15 percent.

At 13:55 hrs Cadila Healthcare was quoting at Rs 1,693.15, up Rs 66.65, or 4.10 percent on the BSE.

(Posted by Nasrin Sultana)

first published: Jan 5, 2015 02:15 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347